IDERA PHARMACEUTICALS, INC. Form 3 March 12, 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION **OMB APPROVAL** FORM 3 Washington, D.C. 20549 OMB Number:

### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

### (Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> BAKER JULIAN			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [IDP]				
(Last)	(First)	(Middle)	(Month/Day/Year) 03/10/2014	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Origina Filed(Month/Day/Year)	
667 MADISON AVENUE, 21ST FLOOR				(Check all applicable)			, , , , , , , , , , , , , , , , , , ,	
	(Street)			X_ Director10% Owner OfficerOther (give title below) (specify below)			6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting	
NEW YORK, NY US 10065						Person _X_Form filed by More than One Reporting Person		
(City) (State) (Zip) <b>Table I - Non-Derivative Securities Beneficially O</b>							neficially Owned	
1.Title of Secu (Instr. 4)	ırity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	<b>.</b>	
Common S	tock		171,548		Ι	See I	Footnotes $(1)$ $(4)$	
Common Stock			1,406,423		Ι	See I	Footnotes $(2)$ $(4)$	
Common S	tock		35.105		I	See I	Footnotes <sup>(3)</sup> <sup>(4)</sup>	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

### Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
Security	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial
	(Month/Day/Year)				

3235-0104

January 31,

2005

0.5

Expires:

response...

Estimated average burden hours per

## Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 3

(Instr. 4)			Derivative Security (Instr. 4)		or Exercise Price of	Form of Derivative	Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2018	Common Stock	2,250,846	\$ 0.47	Ι	See Footnotes $(1)$ (4)	
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2018	Common Stock	17,626,445	\$ 0.47	Ι	See Footnotes $(2)$ (4)	
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2018	Common Stock	439,036	\$ 0.47	Ι	See Footnotes $(3)$ (4)	
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2020	Common Stock	1,752,291	\$ 0.01	Ι	See Footnotes $(1)$ (4)	
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2020	Common Stock	13,722,245	\$ 0.01	Ι	See Footnotes $(2)$ (4)	
Common Stock Warrant ( right to buy)	05/02/2013	05/07/2020	Common Stock	341,791	\$ 0.01	Ι	See Footnotes $(3)$ (4)	
Common Stock Warrant ( right to buy)	09/25/2013	09/25/2020	Common Stock	465,230	\$ 0.01	Ι	See Footnotes $(1)$ (4)	
Common Stock Warrant ( right to buy)	09/25/2013	09/25/2020	Common Stock	3,620,051	\$ 0.01	Ι	See Footnotes $(2)$ (4)	
Common Stock Warrant ( right to buy)	09/25/2013	09/25/2020	Common Stock	90,694	\$ 0.01	Ι	See Footnotes $(3)$ (4)	
Common Stock Warrant ( right to buy)	02/05/2014	02/10/2021	Common Stock	172,406	\$ 0.01	Ι	See Footnotes $(1)$ (4)	
Common Stock Warrant ( right to buy)	02/05/2014	02/10/2021	Common Stock	1,938,274	\$ 0.01	Ι	See Footnotes $(2)$ (4)	
Common Stock Warrant ( right to buy)	02/05/2014	02/10/2021	Common Stock	48,070	\$ 0.01	Ι	See Footnotes $(3)$ (4)	

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	Â	Â	Â		
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	Â	Â	Â		
BAKER FELIX	ÂX	Â	Â	Â		

667 MADISON AVENUE, 21ST F NEW YORK, NY US 10065	LOOR					
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST F NEW YORK, NY US 10065	LOOR	X	Â	Â	Â	
667, L.P. 667 MADISON AVENUE 21ST FL NEW YORK, NY US 10065	LOOR	X	Â	Â	Â	
14159, L.P. 667 MADISION AVENUE, 21ST F NEW YORK, NY US 10065	FLOOR	ÂX	Â	Â	Â	
Baker Brothers Life Sciences LP 667 MADISON AVENUE, 21ST F NEW YORK, NY US 10065	LOOR	ÂX	Â	Â	Â	
Signatures						
/s/ Julian C. Baker						03/12/2014
	<u>**</u> Signature of	of Reporting P	erson			Date
BAKER BROS. ADVISORS LP Na	03/12/2014					
	Date					
/s/ Felix J. Baker	03/12/2014					
	Date					
BAKER BROS. ADVISORS (GP) I Lessing	03/12/2014					
	<u>**</u> Signature of	of Reporting P	erson			Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing						03/12/2014
	Date					

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

As a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock of Idera Pharmaceuticals Inc. (the "Issuer") reported in Table I and Warrants reported in Table II directly held by 667, L.P. ("667"), a limited partnership of which the sole general partner is Baker

Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

As result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table I. Life Sciences L. P. ("Life Sciences"). Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table I. Life Sciences L. P. ("Life Sciences"). Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table I. Life Sciences L. P. ("Life Sciences"). Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table I. Life Sciences L. P. ("Life Sciences"). Life Sciences Capital (GP), LLC, Sciences Capital (GP)

- (2) Table II directly held by Baker Brothers Life Sciences, L.P. ("Life Sciences") a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
- (3) As result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in Table I and Warrants reported in Table II directly held by 14159, L.P. ("14159") a limited partnership of which the sole general partner is 14159 Capital, L.P., a limited partnership of which the sole

(1)

## Edgar Filing: IDERA PHARMACEUTICALS, INC. - Form 3

general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.

Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and

(4) voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

### Â

## **Remarks:**

## Julian C. Baker and Dr. Kelvin Neu, respectively a principal and an employee of the Baker Bros.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.